To describe the prevalence, incidence and current treatment and procedures patterns in a US pediatric population with PAH in MarketScan database during the period 2010-2013
Study Type
OBSERVATIONAL
Enrollment
2,691
As assigned by treating physician; may include following product classes: - Calcium channel blockers/antagonists - Prostanoids (prostaglandins, thromboxanes, prostacyclines) - Endothelin receptor antagonists - PDE-5 inhibitors - SGc stimulators
Unnamed facility
Boston, Massachusetts, United States
Incidence rate of PAH (pulmonary arterial hypertension)
Time frame: Retrospective analysis of three year period
Prevalence rate of PAH
Time frame: Retrospective analysis of three year period
Assigned drug treatment for PAH measured using the MarketScan database
Description of pulmonary hypertension-targeted drugs prescribed in the study population and changes during the study period
Time frame: Retrospective analysis of three year period
Diagnostic procedures performed among PAH patients measured using the MarketScan database
Time frame: Retrospective analysis of three year period
Prevalence of comorbidities among PAH patients
Time frame: Retrospective analysis of three year period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.